Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Liabilities (2016 - 2025)

Ironwood Pharmaceuticals' Total Liabilities history spans 17 years, with the latest figure at $658.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 1.0% year-over-year to $658.7 million; the TTM value through Dec 2025 reached $658.7 million, up 1.0%, while the annual FY2025 figure was $658.7 million, 1.0% up from the prior year.
  • Total Liabilities for Q4 2025 was $658.7 million at Ironwood Pharmaceuticals, roughly flat from $660.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $2.2 billion in Q4 2023 and bottomed at $442.8 million in Q2 2022.
  • The 5-year median for Total Liabilities is $651.7 million (2024), against an average of $690.0 million.
  • The largest annual shift saw Total Liabilities soared 384.15% in 2023 before it plummeted 69.94% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $521.0 million in 2021, then dropped by 13.99% to $448.1 million in 2022, then skyrocketed by 384.15% to $2.2 billion in 2023, then tumbled by 69.94% to $652.2 million in 2024, then rose by 1.0% to $658.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Total Liabilities are $658.7 million (Q4 2025), $660.2 million (Q3 2025), and $651.1 million (Q2 2025).